Congrats to GSK for the approval of Tykerb, another kinase targeting blockbuster, with predictions of up to $2.5B in peak sales. While some have undersold Tykerb as a late-comer to the HER-2+ market that Herceptin already dominates, this approval is important...

SGX posted their 4Q06 and FY2006 figures, so it's a good time to take a look at them.SGX's 3 main programs target Bcr-Abl, c-Met, and JAK2.The Bcr-Abl compound was partnered last May (NVS), which garnered a $25M upfront - though I can't find it on their financial...

....who entered Phase I with SNS-032, a multi-CDK (2, 7, & 9) inhibitor for blood cancers. The other prominent CDK inhibitors in development are from Cyclacel, who does not appear to have publicly identified which CDKs are are in their sights. (AZ also has...

Congrats to GSK for the approval of Tykerb, another kinase targeting blockbuster, with predictions of up to $2.5B in peak sales. While some have undersold Tykerb as a late-comer to the HER-2+ market that Herceptin already dominates, this approval is important...

SGX posted their 4Q06 and FY2006 figures, so it's a good time to take a look at them.SGX's 3 main programs target Bcr-Abl, c-Met, and JAK2.The Bcr-Abl compound was partnered last May (NVS), which garnered a $25M upfront - though I can't find it on their financial...

....who entered Phase I with SNS-032, a multi-CDK (2, 7, & 9) inhibitor for blood cancers. The other prominent CDK inhibitors in development are from Cyclacel, who does not appear to have publicly identified which CDKs are are in their sights. (AZ also has...